Skip to main content

Table 2 Univariate analysis of prognostic factors in progression-free survival

From: The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies

Adverse events Median (months) 95% C.I. of median P value Hazard ratio 95% C.I. of HR P value
Skin    .274    
 Grade 0 (n = 32) 2.8 1.9–3.8   1   
 Grade 1–2 (n = 17) 3.6 1.6–5.6   0.71 0.38–1.32 .278
Skin/vitiligo    .092    
 Grade 0 (n = 30) 2.5 1.6–3.4   1   
 Grade 1–2 (n = 19) 4.6 2.5–6.7   0.59 0.32–1.10 .096
Mucositis    .287    
 Grade 0 (n = 46) 3.1 2.5–3.8   1   
 Grade 1–2 (n = 3) 3.0 0.4–5.6   1.90 0.57–6.29 .296
Colitis    .624    
 Grade 0 (n = 43) 3.2 2.6–3.7   1   
 Grade 1–2 (n = 6) 3.0 2.3–3.7   1.24 0.52–2.96 .626
Liver    .353    
 Grade 0 (n = 47) 3.2 2.7–3.6   1   
 Grade 1–2 (n = 1) 3.1   1.48 0.20–10.99 .700
 Grade 3–5 (n = 1) 2.1   3.89 0.50–30.19 .194
Lung    .005    
 Grade 0 (n = 47) 3.2 2.8–3.5   1   
 Grade 3–5 (n = 2) 0.9   6.71 1.44–31.38 .016
Endocrine    .094    
 Grade 0 (n = 40) 2.7 2.1–3.3   1   
 Grade 1–2 (n = 9) 6.1 2.7–9.6   0.52 0.24–1.13 .100
Fatigue    .024    
 Grade 0 (n = 42) 3.2 2.7–3.7   1   
 Grade 1–2 (n = 7) 2.4 1.5–3.4   2.56 1.09–6.00 .030
Vitiligo    .234    
 Grade 0 (n = 47) 3.0 2.5–3.4   1   
 Grade 1–2 (n = 2) 4.7   0.32 0.04–2.33 .261
Skin/vitiligo/endocrine    .003    
 Grade 0 (n = 26) 2.3 1.7–2.8   1   
 Any grade (n = 23) 4.8 4.3–5.3   0.40 0.21–0.74 .003
Overall    .001    
 Grade 0 (n = 19) 2.5 1.7–3.3   1   
 Grade 1–2 (n = 27) 4.6 2.8–6.4   0.52 0.27–0.98 .042
 Grade 3–5 (n = 3) 2.0 0.2–3.8   4.24 1.1–16.3 .035
  1. C.I. confidence interval